Orphan-drug developers unlikely to leave investors feeling abandoned, says Turner Investments commentary Investment firm’s health-care analysts believe companies developing drugs for rare diseases offer a profitable pharmaceutical niche Business Wire BERWYN, Pa. -- August 1, 2013 Less can be more: pharmaceutical companies developing so-called “orphan” drugs, or treatments for rare diseases with 100,000 or fewer patients, can enjoy a highly profitable niche in the industry, according to the latest Sector Focus commentary from Turner Investments. Titled Adopting orphan drugs can be highly profitable, the piece was written by the five Turner analysts who cover the health-care sector: Heather McMeekin, portfolio manager/global equity analyst; Vijay Shankaran, senior portfolio manager/global equity analyst; Frank Sustersic, senior portfolio manager/global equity analyst; Theresa Tran, global equity analyst, and Michael Tung, global equity analyst. Turner Investments, based in Berwyn, Pennsylvania, publishes Sector Focus commentaries monthly as part of the continuing efforts of its five teams of security analysts to monitor market sectors for its growth-stock portfolios. According to the analysts, “Because orphan drugs have substantial treatment impact – they’re often much stronger than other drugs – hundreds or thousands of new patients tend to emerge when they learn of the drugs’ beneficial effects,” thus increasing the initial patient base. And as patients live longer as a result of the drugs, demand for the drugs grows even more. What’s more, federal incentives for companies to develop orphan drugs, like tax incentives and exclusive marketing rights, provide developers with considerable pricing power. In turn, that can provide investors with a return on investment 1.7 times greater than that of non-orphan drugs, according to EvaluatePharma. The analysts believe Aegerion Pharmaceuticals, Alexion Pharmaceuticals, NPS Pharmaceuticals, and ViroPharma appear to be well positioned to benefit from the growth of orphan drugs. To read this July 2013 Sector Focus in its entirety, click on this link to the Turner Investments Web site: www.turnerinvestments.com/health-care. Or call 484.329.2407 for a free copy of the piece. * The views, opinions, and content presented are for informational purposes only. They are not intended to reflect a current or past recommendation; investment, legal, tax, or accounting advice of any kind; or a solicitation of an offer to buy or sell any securities or investment services. Except as otherwise specified, any companies, sectors, securities, and/or markets discussed are solely for illustrative purposes regarding economic trends and conditions or investment process and may or may not be held by Turner, the Turner Funds, or other investment vehicles or accounts managed by Turner or its affiliates. Past performance is no guarantee of future results. Turner Investments refers to Turner Investments, L. P., its subsidiaries, and affiliates. Nothing presented should be considered to be an offer to provide any Turner product or service in any jurisdiction that would be unlawful under the securities laws of that jurisdiction. Turner Investments, founded in 1990, is an investment firm based in Berwyn, Pennsylvania. As of June 30, 2013, we managed more than $8 billion in growth, global/international, and long/short investment portfolios in stocks to both institutions and individuals. As of June 30, 2013, Turner held in client accounts 246,170 shares of Aegerion Pharmaceuticals, 198,714 shares of Alexion Pharmaceuticals, 3.1 million shares of NPS Pharmaceuticals, and 883,973 shares of ViroPharma. Contact: Turner Investments Abbi Anderson, 484-329-2407 email@example.com
Orphan-drug developers unlikely to leave investors feeling abandoned, says Turner Investments commentary
Press spacebar to pause and continue. Press esc to stop.